FindTrial
Sign In

Defactinib Hydrochloride

DRUG3 trials

Sponsors

National Cancer Institute (NCI), Thomas Jefferson University

Conditions

Advanced LymphomaAdvanced Malignant Solid NeoplasmBladder CarcinomaBreast CarcinomaCervical CarcinomaColon CarcinomaColorectal CarcinomaEndometrial Carcinoma

Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Active, not recruitingNCT02465060
National Cancer Institute (NCI)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma +49
Start: 2015-08-17End: 2026-12-31Target: 6452Updated: 2026-04-03
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)
Active, not recruitingNCT04439331
National Cancer Institute (NCI)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3
Start: 2015-11-19End: 2027-01-15Updated: 2026-04-03
Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
TerminatedNCT04720417
Thomas Jefferson UniversityMetastatic Uveal Melanoma
Start: 2021-01-26End: 2024-04-30Updated: 2025-07-15

Related Papers

Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
2025-10-09
Comprehensive genomic profiling of matched ctDNA and tissue from patients with less common cancers enrolled in but not eligible for a treatment arm of the NCI-MATCH trial.
Journal of Clinical Oncology2025-05-281 citations
Molecular profiling of plasma from matched NCI-MATCH gynecological cancers.
Journal of Clinical Oncology2024-06-011 citations
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial
The Oncologist2024-05-306 citations
Abstract CT260: A phase II trial of defactinib combined with avutometinib in patients with metastatic uveal melanoma
Cancer Research2024-04-052 citations
Abstract B007: Concordance between tumor tissue and plasma genotyping in NCI-MATCH Trial (EAY131)
Molecular Cancer Therapeutics2023-12-01
Revolutionizing cancer drug development: Harnessing the potential of basket trials.
2023-11-0720 citations
The NCI-MATCH trial: lessons for precision oncology.
2023-06-15103 citations
Phase II study of crizotinib in patients with <i>MET</i> amplification and <i>MET</i> exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.
Journal of Clinical Oncology2023-06-012 citations
Discovery of gene fusions in driver-negative NCI-MATCH screening samples.
Journal of Clinical Oncology2023-06-011 citations
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Nature Medicine2023-04-14244 citations
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Clinical Cancer Research2023-01-2055 citations
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
npj Precision Oncology2022-10-2715 citations
Abstract 2438: Determining the role of non-mutated C-Raf kinase in metastatic disease
Cancer Research2022-06-15
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
2022-06-077 citations
Phase II study of vismodegib in patients with <i>SM</i>O or <i>PTCH1</i> mutated tumors: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T.
Journal of Clinical Oncology2022-06-013 citations
Molecular predictors of response among patients with MMRd tumors treated on NCI-MATCH Arm Z1D.
Journal of Clinical Oncology2022-06-01
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers
The Oncologist2022-04-1445 citations
Abstract P2-13-24: Distinct HER2 allele specific therapeutic response and preclinical efficacy of poziotinib in metastatic ER+ HER2 mutant breast cancer
Cancer Research2022-02-151 citations
A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.
Journal of Clinical Oncology2021-05-208 citations

20 more papers not shown